PSTX - Poseida Therapeutics, Inc.
IEX Last Trade
9.485
0.005 0.053%
Share volume: 10,853
Last Updated: Thu 26 Dec 2024 08:30:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$9.48
0.00
0.05%
Fundamental analysis
17%
Profitability
8%
Dept financing
16%
Liquidity
64%
Performance
15%
Performance
5 Days
0.11%
1 Month
1.17%
3 Months
219.53%
6 Months
284.21%
1 Year
182.44%
2 Year
84.99%
Key data
Stock price
$9.48
DAY RANGE
$9.44 - $9.49
52 WEEK RANGE
$2.07 - $9.58
52 WEEK CHANGE
$172.70
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Mark J. Gergen
Region: US
Website: poseida.com
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: poseida.com
Employees: 260
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC)
Recent news